Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

Orientation to BPAN: What You Need to Know

At a Glance

BPAN is a rare genetic brain disorder caused by a change in WDR45. It often starts with developmental and language delays and can later bring stiffness, slow movement, tremors, or twisting movements. Genetic testing helps confirm it, and support changes over time.

Receiving a diagnosis of Beta-propeller Protein-Associated Neurodegeneration (BPAN) can feel like entering a new and unfamiliar world. While this moment marks the end of what many families describe as a long and exhausting “diagnostic odyssey,” it also signals the start of a journey focused on understanding your or your loved one’s unique needs [1][2]. BPAN is an ultra-rare disorder, meaning it affects a very small number of people worldwide, but you are now part of a community of families and researchers dedicated to this condition [3].

Understanding the Rarity of BPAN

BPAN is classified as a form of Neurodegeneration with Brain Iron Accumulation (NBIA), a group of rare genetic disorders where iron builds up in specific areas of the brain. Within this group, BPAN is one of the most common forms, representing approximately 7% to 35% of all NBIA cases [3][4].

For context, the entire group of NBIA disorders is estimated to affect only about 1 to 3 people per million [5]. Because it is so rare, many healthcare providers may have never seen a case before. Finding a diagnosis often requires specialized genetic testing, such as Whole Exome Sequencing (WES), which reads through a person’s genetic code to find the specific pathogenic variant (disease-causing change) in the WDR45 gene that causes BPAN [6][7].

The Two Phases of BPAN

Clinicians describe BPAN as having a biphasic (two-phase) course. This means the condition typically looks different in early childhood than it does later in life, although phases can overlap and progression varies widely between individuals [8].

  • Phase 1: Early Childhood (The Neurodevelopmental Phase)
    During the first several years, the primary focus is often on global developmental delay. Most individuals experience significant delays in reaching milestones like sitting or walking [1]. A hallmark of this phase is a “disproportionate” delay in expressive language, meaning children often understand far more than they can say out loud [8][9]. Many also develop epilepsy (seizures) during these years, though these often become easier to manage or may even stop as the individual grows older [8][1].

  • Phase 2: Adolescence or Early Adulthood (The Neurodegenerative Phase)
    After a variable period of relative stability, a second phase typically begins. During this time, new symptoms may emerge, including parkinsonism (tremors, slowness of movement, or stiffness) and dystonia (involuntary muscle contractions that cause twisting movements) [8][10]. It is also during this later stage that brain iron accumulation usually becomes visible on an MRI (Magnetic Resonance Imaging) [11][12].

Why Most Patients are Female

BPAN is an X-linked dominant disorder. This means the gene responsible, WDR45, is located on the X chromosome. Because females have two X chromosomes and males have only one, the inheritance pattern is unique.

  • Strong Female Predominance: The majority of individuals diagnosed with BPAN are female [3].
  • X-Linked Dominant Inheritance: This pattern suggests that severe genetic changes may be lethal to many males before birth. However, affected males who survive do exist, sometimes experiencing severe symptoms or carrying the variant in only some of their cells (a condition called mosaicism) [3][13]. In females, symptoms can vary significantly, partially due to X-inactivation, though this is not a reliable test for predicting individual severity.
  • De Novo Variants and Recurrence: In most cases, the genetic change is de novo, meaning it happened spontaneously and was not inherited from either parent [3][6]. While a de novo variant lowers recurrence risk, it is not strictly zero because parental germline mosaicism is possible. If a mother carries the pathogenic variant, she has a 50% chance of passing it on in each pregnancy. Doctors highly recommend formal genetic counseling for the family [13].

Validating the Emotional Journey

The path to a BPAN diagnosis is rarely straightforward. Many families spend years visiting different specialists and undergoing various tests before receiving an answer. It is common for early brain scans to appear normal because the characteristic iron buildup often does not appear until later in life [11][14].

Research into the lives of BPAN families highlights that while the diagnosis can be overwhelming, it also provides a roadmap for care. Caregivers often report that communication and social functioning are their highest priorities [2]. By understanding the two-phase nature of the disease, you can work with your medical team to provide supportive care—such as physical, occupational, and speech therapy—that adapts over time [8][2]. Although BPAN is a lifelong journey, you are not walking it alone; specialized clinics and family advocacy groups exist to bridge the gap between research and daily life.

Common questions in this guide

What is BPAN?
BPAN is a rare genetic disorder caused by a disease-causing change in the WDR45 gene. It belongs to the neurodegeneration with brain iron accumulation group and can affect development, communication, seizures, and movement over time.
What are the two phases of BPAN?
The early phase usually involves developmental delay, especially difficulty speaking, and may include seizures. After a period of relative stability, a later phase can bring movement problems such as tremors, stiffness, slowness, or involuntary twisting, although the timing and progression vary.
How is BPAN diagnosed?
BPAN is diagnosed through clinical evaluation and genetic testing that identifies a disease-causing WDR45 variant; whole exome sequencing may be used. Brain MRI can initially look normal because iron accumulation often becomes visible only later.
Why does BPAN affect more females than males?
BPAN is linked to the X chromosome, and females have two X chromosomes while males have one. Severe WDR45 changes may prevent some affected males from surviving before birth, but males who survive can have BPAN, including cases involving mosaicism, in which the change is present in only some cells.
Is BPAN inherited, and could it affect another child in the family?
Most BPAN cases are caused by a new genetic change that was not inherited from either parent, but the chance of recurrence is not zero because a parent can have the change in some reproductive cells. If a mother carries the disease-causing WDR45 variant, each pregnancy has a 50% chance of inheriting it. Genetic counseling and parental testing can clarify a family's risk.
What care and therapies can help someone with BPAN?
BPAN care is individualized and may involve neurologists, neurogenetics specialists, movement-disorder clinicians, and genetic counselors. Physical, occupational, and speech therapy can support movement, daily activities, communication, and changing needs across the two phases.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific WDR45 variant was found in our genetic report, and is it considered pathogenic?
  2. 2.Does the genetic report indicate a de novo variant, and what does that mean for our family's recurrence risk?
  3. 3.Given that this condition often has two phases, what signs should we watch for over time?
  4. 4.What multidisciplinary specialists (such as neurogenetics or adult movement disorders) should be part of our core care team?
  5. 5.Is parental testing or formal genetic counseling recommended for our family?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Quantitative retrospective natural history modeling of WDR45-related developmental and epileptic encephalopathy - a systematic cross-sectional analysis of 160 published cases.

    Saffari A, Schröter J, Garbade SF, et al.

    Autophagy 2022; (18(7)):1715-1727 doi:10.1080/15548627.2021.1990671.

    PMID: 34818117
  2. 2

    Determination of Health Concepts in β-Propeller Protein-Associated Neurodegeneration.

    Kotes E, Gavazzi F, Woidill S, et al.

    Journal of child neurology 2025; (40(1)):15-25 doi:10.1177/08830738241283932.

    PMID: 39376195
  3. 3

    Lessons from a pair of siblings with BPAN.

    Zarate YA, Jones JR, Jones MA, et al.

    European journal of human genetics : EJHG 2016; (24(7)):1080-3 doi:10.1038/ejhg.2015.242.

    PMID: 26577041
  4. 4

    High frequency of beta-propeller protein-associated neurodegeneration (BPAN) among patients with intellectual disability and young-onset parkinsonism.

    Nishioka K, Oyama G, Yoshino H, et al.

    Neurobiology of aging 2015; (36(5)):2004.e9-2004.e15.

    PMID: 25744623
  5. 5

    Metabolic impairments in neurodegeneration with brain iron accumulation.

    Wydrych A, Pakuła B, Janikiewicz J, et al.

    Biochimica et biophysica acta. Bioenergetics 2025; (1866(1)):149517 doi:10.1016/j.bbabio.2024.149517.

    PMID: 39366438
  6. 6

    Phenotypic and Imaging Spectrum Associated With WDR45.

    Adang LA, Pizzino A, Malhotra A, et al.

    Pediatric neurology 2020; (109()):56-62 doi:10.1016/j.pediatrneurol.2020.03.005.

    PMID: 32387008
  7. 7

    Functional mRNA analysis reveals aberrant splicing caused by novel intronic mutation in WDR45 in NBIA patient.

    Willoughby J, Duff-Farrier C, Desurkar A, et al.

    American journal of medical genetics. Part A 2018; (176(5)):1049-1054 doi:10.1002/ajmg.a.38656.

    PMID: 29681108
  8. 8

    Consensus clinical management guideline for beta-propeller protein-associated neurodegeneration.

    Wilson JL, Gregory A, Kurian MA, et al.

    Developmental medicine and child neurology 2021; (63(12)):1402-1409 doi:10.1111/dmcn.14980.

    PMID: 34347296
  9. 9

    Psychometric outcome measures in beta-propeller protein-associated neurodegeneration (BPAN).

    Gavazzi F, Pierce SR, Vithayathil J, et al.

    Molecular genetics and metabolism 2022; (137(1-2)):26-32 doi:10.1016/j.ymgme.2022.07.009.

    PMID: 35878504
  10. 10

    Beta-Propeller Protein-Associated Neurodegeneration (BPAN) Detected in a Child with Epileptic Spasms.

    Kaleka G, McCormick ME, Krishnan A

    Cureus 2019; (11(8)):e5404 doi:10.7759/cureus.5404.

    PMID: 31632858
  11. 11

    Serial MRI alterations of pediatric patients with beta-propeller protein associated neurodegeneration (BPAN).

    Kimura Y, Sato N, Ishiyama A, et al.

    Journal of neuroradiology = Journal de neuroradiologie 2021; (48(2)):88-93 doi:10.1016/j.neurad.2020.04.002.

    PMID: 32335071
  12. 12

    Substantia Nigra Swelling and Dentate Nucleus T2 Hyperintensity May Be Early Magnetic Resonance Imaging Signs of β-Propeller Protein-Associated Neurodegeneration.

    Russo C, Ardissone A, Freri E, et al.

    Movement disorders clinical practice 2019; (6(1)):51-56 doi:10.1002/mdc3.12693.

    PMID: 30746416
  13. 13

    De novo variants in WDR45 underlie beta-propeller protein-associated neurodegeneration in five independent families.

    Tang X, Lan X, Song X, et al.

    Molecular genetics & genomic medicine 2020; (8(11)):e1499 doi:10.1002/mgg3.1499.

    PMID: 33037762
  14. 14

    Expanding the Spectrum of Early Neuroradiologic Findings in β Propeller Protein-Associated Neurodegeneration.

    Papandreou A, Soo AKS, Spaull R, et al.

    AJNR. American journal of neuroradiology 2022; (43(12)):1810-1814 doi:10.3174/ajnr.A7693.

    PMID: 36328404

This BPAN overview is for informational purposes only and does not replace medical advice. A neurologist, geneticist, and genetic counselor can help interpret your diagnosis and plan care.

Get notified when new evidence is published on Beta-propeller protein-associated neurodegeneration.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.